Latest news and press releases about Evaxion Biotech A/S (EVAX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases.
Price
| Price | $3.03 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | DK |
Valuation Ratios
| Price / Book | 0.13 |
| EV / EBITDA | -2.08 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -45.23% |
| Return on Invested Capital | -33.44% |
| Return on Assets | -27.13% |
| Gross Margin | 100.00% |
| Operating Margin | -115.98% |
| Net Margin | -115.49% |
Related companies: ANVS · BCAB · BTAI · CELU · GBIO · MURA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of EVAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks